Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

The evolution of rectal cancer care, including the rise of patients assigned to “watch and wait” protocols, will be included in the new standards.

A team of colleagues at Fox Chase Cancer Center recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for patients with melanoma.

There's no routine screening test for pancreatic cancer, and symptoms can be mistaken for common illnesses.

There's no routine screening test for pancreatic cancer, and symptoms can be mistaken for common illnesses.

Annals of Surgical Oncology -

Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS–HIPEC) is an effective but costly procedure for select patients with peritoneal malignancies. The impact of progres...

Background US News and World Report (USNWR) hospital rankings influence patient choice of hospital, but their association with surgical outcomes remains ill-defined. We sought to characterize clinical...

Purpose This study aimed to develop postsurgical progression/hyperprogression recurrence (type III-IV recurrence) prediction models for hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MaVI) and to guide treatment strategies in the accurate healthcare era. Patients and methods 393 HCC patients with MaVI from two central hospitals made up the entire study population. In developmental (290 patients) and validation (103 patients) cohorts, all patients were randomized into one or the other. Two prediction models for type III-IV recurrence were developed, based on the findings of univariate and multivariate analysis in the development cohort, and multidimensional verification was carried out in both cohorts. Results The postoperative recurrence rate of type III-IV in 393 HCC patients with MaVI was 70.9%. Young age, large tumor size (≥ 10 cm), node number, incomplete tumor capsule, postoperative complications, and high Ki67 index were the independent risk factors for relapse of type III-IV. In the development cohort, two nomograms (pre- and postoperative) had the Area Under the ROC curve (AUC) of 0.827 and 0.891, respectively. The two nomograms performed well, according to multidimensional verification methods such as clinical impact curves, decision curve analysis (DCA), and calibration curves. The validation cohort saw similar encouraging results. Both nomograms could separate patients into two distinct prognosis subgroups with ideal cutoff values of 170.3 presurgery and 175.0 postsurgery (both P < 0.05). Conclusion We constructed two novel and potentially clinically valuable models for predicting type III-IV recurrence. These two models can develop strategies for treating those suffering from HCC with MaVI owing to their strong prediction performance and availability.